Announcement time of this financial report: 2023-10-27 16:26:03

Jiangsu Kindick Biotechnology Co., Ltd. (stock code: 688670) is an enterprise specializing in the research, development, production and sales of human vaccines. Its main products include human vaccines against infectious diseases such as influenza, rabies, chicken pox, herpes zoster and pneumonia. The company has put on the market a tetravalent split influenza virus vaccine, which is superior to the standards of Chinese Pharmacopoeia and European Pharmacopoeia in terms of immune efficacy and safety.

In terms of assets and liabilities, Kingdick's total assets at the end of the third quarter of 2023 were 1.719 billion yuan, down 5.89 percent from 1.827 billion yuan at the end of the previous year. The total debt was 288 million yuan, a decrease of 21.53% compared with 367 million yuan at the end of last year. The net asset was 1.431 billion yuan, down 1.99% from 1.46 billion yuan at the end of last year. The asset-liability ratio was 16.76%, down 3.34 percentage points from 20.1% at the end of the previous year.

In terms of profit, the company's operating income in the third quarter of 2023 was 121 million yuan, down 45.16% from 220 million yuan in the same period last year. Operating profit was-16.7096 million yuan, down 126.78% from 62.3612 million yuan in the same period last year. The operating cost was 20.684 million yuan, a decrease of 36.45% compared with 32.535 million yuan in the same period last year. The net profit was-11.0771 million yuan, down 119.92% from 55.6156 million yuan in the same period last year. The gross profit margin was 82.88%, down 2.36 percentage points from 85.24% in the same period last year. The net interest rate was-9.17%, down 34.41 percentage points from 25.24% in the same period last year. Return on equity (ROE) was-0.77%, down 4.57 percentage points from 3.79% at the end of last year.

In terms of cash flow, the net cash flow generated by the company's operating activities in the third quarter of 2023 was 61.7614 million yuan, an increase of 152.56% compared with 24.4542 million yuan in the same period last year. The cash inflow from operating activities totaled 329 million yuan, an increase of 27.52% compared with 258 million yuan in the same period last year. The cash outflow from business activities totaled 268 million yuan, an increase of 15.02% compared with 233 million yuan in the same period last year.

To sum up, the operating condition of Kingdick Company in the third quarter of 2023 is characterized by a decline in operating income and net profit and a significant increase in net cash flow. The decline in operating income and net profit was mainly due to the company's temporary suspension of production and no sales income in the third quarter, while the company reported an asset impairment loss of 31.9669 million yuan in the reporting period. The increase in net cash flow is mainly due to the strengthening of the management of accounts receivable and the increase in sales rebates compared with the same period last year.

For investors, although Kingdick's operating income and net profit declined in the third quarter of 2023, the increase in its net cash flow indicates an increase in cash inflow from the company's operating activities, which is beneficial to the company's long-term development. At the same time, the company has strong R & D strength and market development ability in the field of human vaccine, and is expected to make greater development in the field of human vaccine in the future. Therefore, investors can continue to pay attention to the operating conditions and performance changes of Kingdick in order to make more accurate investment decisions.

This article only represents the judgment made by the analyst himself or the analyst on the basis of AI analysis, and can not be used as any investment index, nor does it constitute any investment advice. The original intention of this paper is to help investors analyze and judge the capital market data in the most intuitive and fast way and from the most professional perspective.